From: CyclinD1, a prominent prognostic marker for endometrial diseases
Parameter a vs. Parameter b | Positives (Parameter a) | Positives (Parameter b) | χ2value* | p value* |
---|---|---|---|---|
Simple hyperplasia vs. atypical complex hyperplasia | 8/27(30%) | 20/41(49%) | 2.465 | 0.116 |
Simple hyperplasia vs. endometrioid carcinoma | 8/27(30%) | 54/103(52%) | 4.457 | 0.035 |
Simple hyperplasia vs. endometrial serous carcinoma | 8/27(30%) | 8/21(38%) | 0.381 | 0.537 |
Simple hyperplasia vs. clear cell carcinoma | 8/27(30%) | 6/9(67%) | 3.50*** | 0.111** |
Atypical complex hyperplasia vs. endometrioid carcinoma | 20/41(49%) | 54/103(52%) | 0.156 | 0.693 |
Atypical complex hyperplasia vs. endometrial serous carcinoma | 20/41(49%) | 8/21(38%) | 0.640 | 0.424 |
Atypical complex hyperplasia vs. clear cell carcinoma | 20/41(49%) | 6/9(67%) | 4.32*** | 0.467** |
Endometrioid carcinoma vs. endometrial serous carcinoma | 54/103(52%) | 8/21(38%) | 1.433 | 0.231 |
Endometrioid carcinoma vs. clear cell carcinoma | 54/103(52%) | 6/9(67%) | 4.18*** | 0.500** |
Endometrial serous carcinoma vs. clear cell carcinoma | 8/21(38%) | 6/9(67%) | 4.20*** | 0.236 |